Clinical Trial Update: Innate Immunity Stimulation Via TLR9 in Early AD [Phase 1]

View source ↗

Summary

A Phase 1 trial at NYU Langone Health is evaluating stimulation of innate immunity via TLR9 in individuals with mild cognitive impairment or Alzheimer's disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Snippet

Sponsor: NYU Langone Health | Conditions: Mild Cognitive Impairment, Alzheimer Dementia | Phase 1 | Status: RECRUITING